Marcus Fändrich

Universität Ulm, Ulm, Baden-Württemberg, Germany

Are you Marcus Fändrich?

Claim your profile

Publications (84)505.84 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Extracellular alpha-synuclein (αsyn) oligomers, associated to exosomes or free, play an important role in the pathogenesis of Parkinson's disease (PD). Increasing evidence suggests that these extracellular moieties activate microglia leading to enhanced neuronal damage. Despite extensive efforts on studying neuroinflammation in PD, little is known about the impact of age on microglial activation and phagocytosis, especially of extracellular αsyn oligomers. Here, we show that microglia isolated from adult mice, in contrast to microglia from young mice, display phagocytosis deficits of free and exosome-associated αsyn oligomers combined with enhanced TNFα secretion. In addition, we describe a dysregulation of monocyte subpopulations with age in mice and humans. Accordingly, human monocytes from elderly donors also show reduced phagocytic activity of extracellular αsyn. These findings suggest that these age-related alterations may contribute to an increased susceptibility to pathogens or abnormally folded proteins with age in neurodegenerative diseases.
    Full-text · Article · Nov 2015 · Acta Neuropathologica
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a fatal neurodegenerative disorder in humans and the main cause of dementia in aging societies. The disease is characterized by the aberrant formation of β-amyloid (Aβ) peptide oligomers and fibrils. These structures may damage the brain and give rise to cerebral amyloid angiopathy, neuronal dysfunction, and cellular toxicity. Although the connection between AD and Aβ fibrillation is extensively documented, much is still unknown about the formation of these Aβ aggregates and their structures at the molecular level. Here, we combined electron cryomicroscopy, 3D reconstruction, and integrative structural modeling methods to determine the molecular architecture of a fibril formed by Aβ(1-42), a particularly pathogenic variant of Aβ peptide. Our model reveals that the individual layers of the Aβ fibril are formed by peptide dimers with face-to-face packing. The two peptides forming the dimer possess identical tilde-shaped conformations and interact with each other by packing of their hydrophobic C-terminal β-strands. The peptide C termini are located close to the main fibril axis, where they produce a hydrophobic core and are surrounded by the structurally more flexible and charged segments of the peptide N termini. The observed molecular architecture is compatible with the general chemical properties of Aβ peptide and provides a structural basis for various biological observations that illuminate the molecular underpinnings of AD. Moreover, the structure provides direct evidence for a steric zipper within a fibril formed by full-length Aβ peptide.
    Full-text · Article · Sep 2015 · Proceedings of the National Academy of Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: Solvation and hydration are key factors for determining the stability and folding of proteins, as well as the formation of amyloid fibrils and related polypeptide aggregates. Using attenuated total reflectance Fourier-transform infrared (ATR-FTIR) and solid-state (ss)NMR spectroscopy, we find that the Aβ peptide experiences a remarkable conformational switch from β to α secondary structure upon solvent removal by lyophilization of oligomers. This transition is, contrary to Aβ fibrils, independent of concentration of organic co-solvents or co-solutes, and reversible upon re-addition of the solvent. Our data illuminate a previously unnoted secondary structural plasticity of the Aβ peptide in amyloid oligomers that could bear relevance for Aβ's interactions with cellular structures of low polarity. Copyright © 2015. Published by Elsevier Ltd.
    No preview · Article · May 2015 · Journal of Molecular Biology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amyloid β (Aβ) fibrils are strongly involved in the pathogenesis of Alzheimer's diseases. The Aβ oligomers represent a non-fibrillar intermediate state of fibril formation.Here we explored the potential of Aβ peptide oligomers as a novel class of biological nanoparticles for macrophage targeting. This study shows that Aβ(1-40) peptide oligomers have a near-spheroid shape and due to a β-sheet assembly possess a compact, quasi-crystalline architecture. Additionally, FRET analysis revealed that Aβ(1-40) are structurally dynamic. Hence, they represent highly structured and biocompatible nanoparticles, which can be readily degraded by natural enzymes. Macrophages play a major role in immunity and tissue repair. However, recent evidence implicates them in progression of atherosclerosis, fibrosis, tumor initiation and development. In this context, specific labeling and imaging of macrophages are of special interest for diagnostic and therapeutic applications. We found that oligomeric Aβ(1-40) is preferentially taken up by macrophages compared to peripheral mononuclear cells. This prompted us to conjugate oligomeric Aβ(1-40) to nanoparticles composed of a superparamagnetic iron oxide (SPIO) core and a polymeric shell used to increase contrast in magnetic resonance imaging (MRI). Such functionalization enabled the preferential uptake of SPIO-Aβ contrast agents by macrophages. Thus, functionalization with Aβ oligomers might be used to diagnose disease-associated macrophage accumulation by MRI.
    No preview · Article · Apr 2015 · The FASEB Journal
  • Dietmar Rudolf Thal · Marcus Fändrich

    No preview · Article · Jan 2015 · Acta Neuropathologica
  • Magdalena Bereza · Marcus Faendrich
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer’s disease characteristically involves the deposition of Aβ peptide as fibril-containing amyloid plaques. Examination of Aβ amyloid fibrils formed in vitro revealed a profound structural polymorphism of the filaments. The structure of polymorphic Aβ fibrils has been investigated with cryoelectron microscopy or nuclear magnetic resonance spectroscopy. This research revealed the common protofilament substructure of Aβ fibril morphologies. However, there are also significant differences in the structural models of fibrillar Aβ peptide that have been put forward by the different experimental techniques. X-ray crystallography of peptide fragments derived from Aβ peptide further illuminated the structural variability of the cross-β conformations adopted. This chapter provides a general overview of the data on polymorphism in Aβ fibrils, and presents current concepts to classify and to rationalize this phenomenon. As evidence suggests that polymorphism of Aβ fibril structures occurs in vivo, possible biologic consequences of this phenomenon are discussed.
    No preview · Chapter · Dec 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Amyloid deposits are common in various tissues as a consequence of misfolded proteins. However, secretory protein and peptides are often stored in membrane coated granules as functional amyloids. In this article, we present a detailed characterization of in vitro generated amyloid fibrils from human parathyroid hormone (hPTH(1-84)). Fully mature fibrils could be obtained after a short lag phase within less than one hour at 65°C. These fibrils showed all characteristic of a cross-β structure. Protease cleavage combined with mass spectrometry identified the central region of the peptide hormone involved in the fibril core formation. EGCG, an inhibitor of amyloid fibril formation, showed binding to residues in the peptide monomers corresponding to the later fibril core and thus explaining the inhibition of the fibril growth. Conformational and dynamic studies by solid-state NMR further corroborated the cross-β core of the fibrils, but also identified highly mobile segments with random coil structure not belonging to the rigid fibril core. Copyright © 2014. Published by Elsevier B.V.
    Full-text · Article · Dec 2014 · Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is characterized by β-amyloid plaques and intraneuronal τ aggregation usually associated with cerebral amyloid angiopathy (CAA). Both β-amyloid plaques and CAA deposits contain fibrillar aggregates of the amyloid β-peptide (Aβ). Aβ plaques and CAA develop first in neocortical areas of preclinical AD patients and, then, expand in a characteristic sequence into further brain regions with end-stage pathology in symptomatic AD patients. Aβ aggregates are not restricted to amyloid plaques and CAA. Soluble and several types of insoluble non-plaque- and non-CAA-associated Aβ aggregates have been described. Amyloid fibrils are products of a complex self-assembly process that involves different types of transient intermediates. Amongst these intermediate species are protofibrils and oligomers. Different variants of Aβ peptides may result from alternative processing or from mutations that lead to rare forms of familial AD. These variants can exhibit different self-assembly and aggregation properties. In addition, several post-translational modifications of Aβ have been described that result, for example, in the production of N-terminal truncated Aβ with pyroglutamate modification at position 3 (AβN3pE) or of Aβ phosphorylated at serine 8 (pSer8Aβ). Both AβN3pE and pSer8Aβ show enhanced aggregation into oligomers and fibrils. However, the earliest detectable soluble and insoluble Aβ aggregates in the human brain exhibit non-modified Aβ, whereas AβN3pE and pSer8Aβ are detected in later stages. This finding indicates the existence of different biochemical stages of Aβ aggregate maturation with pSer8Aβ being related mainly to cases with symptomatic AD. The conversion from preclinical to symptomatic AD could thereby be related to combined effects of increased Aβ concentration, maturation of aggregates and spread of deposits into additional brain regions. Thus, the inhibition of Aβ aggregation and maturation before entering the symptomatic stage of the disease as indicated by the accumulation of pSer8Aβ may represent an attractive treatment strategy for preventing disease progression.
    No preview · Article · Dec 2014 · Acta Neuropathologica
  • Gunilla T Westermark · Marcus Fändrich · Per Westermark
    [Show abstract] [Hide abstract]
    ABSTRACT: The understanding of why and how proteins misfold and aggregate into amyloid fibrils has increased considerably during recent years. Central to amyloid formation is an increase in the frequency of the β-sheet structure, leading to hydrogen bonding between misfolded monomers and creating a fibril that is comparably resistant to degradation. Generation of amyloid fibrils is nucleation dependent, and once formed, fibrils recruit and catalyze the conversion of native molecules. In AA amyloidosis, the expression of cytokines, particularly interleukin 6, leads to overproduction of serum amyloid A (SAA) by the liver. A chronically high plasma concentration of SAA results in the aggregation of amyloid into cross-β-sheet fibrillar deposits by mechanisms not fully understood. Therefore, AA amyloidosis can be thought of as a consequence of long-standing inflammatory disease. This review summarizes current knowledge about AA amyloidosis. The systemic amyloidoses have been regarded as intractable conditions, but improvements in the understanding of fibril composition and pathogenesis over the past decade have led to the development of a number of different therapeutic approaches with promising results. Expected final online publication date for the Annual Review of Pathology: Mechanisms of Disease Volume 10 is January 24, 2015. Please see http://www.annualreviews.org/catalog/pubdates.aspx for revised estimates.
    No preview · Article · Oct 2014 · Annual Review of Pathology Mechanisms of Disease
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amyloid oligomers are nonfibrillar polypeptide aggregates linked to diseases, such as Alzheimer's and Parkinson's. Here we show that these aggregates possess a compact, quasi-crystalline architecture that presents significant nanoscale regularity. The amyloid oligomers are dynamic assemblies and are able to release their individual subunits. The small oligomeric size and spheroid shape confer diffusible characteristics, electrophoretic mobility, and the ability to enter hydrated gel matrices or cells. We finally showed that the amyloid oligomers can be labeled with both fluorescence agents and iron oxide nanoparticles and can target macrophage cells. Oligomer amyloids may provide a new biological nanomaterial for improved targeting, drug release, and medical imaging.
    No preview · Article · Oct 2014 · ACS Nano
  • Christian Haupt · Marcus Fändrich
    [Show abstract] [Hide abstract]
    ABSTRACT: The aberrant self-assembly of polypeptide chains into amyloid structures is a common phenomenon in several neurodegenerative diseases, systemic amyloidosis, and ‘normal’ aging. Improvements in laboratory-scale detection of these structures, their clinical diagnosis, and the treatment of disease likely depend on the advent of new molecules that recognize particular states or induce their clearance in vivo. This review will describe what biotechnology can do to generate proteinaceous amyloid-binders, explain their molecular recognition mechanisms, and summarize possibilities to functionalize further these ligands for specific applications.
    No preview · Article · Oct 2014 · Trends in Biotechnology
  • Source

    Full-text · Dataset · Aug 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unlabelled: Semen enhances HIV infection in vitro, but how long it retains this activity has not been carefully examined. Immediately postejaculation, semen exists as a semisolid coagulum, which then converts to a more liquid form in a process termed liquefaction. We demonstrate that early during liquefaction, semen exhibits maximal HIV-enhancing activity that gradually declines upon further incubation. The decline in HIV-enhancing activity parallels the degradation of peptide fragments derived from the semenogelins (SEMs), the major components of the coagulum that are cleaved in a site-specific and progressive manner upon initiation of liquefaction. Because amyloid fibrils generated from SEM fragments were recently demonstrated to enhance HIV infection, we set out to determine whether any of the liquefaction-generated SEM fragments associate with the presence of HIV-enhancing activity. We identify SEM1 from amino acids 86 to 107 [SEM1(86-107)] to be a short, cationic, amyloidogenic SEM peptide that is generated early in the process of liquefaction but that, conversely, is lost during prolonged liquefaction due to the activity of serine proteases. Synthetic SEM1(86-107) amyloids directly bind HIV-1 virions and are sufficient to enhance HIV infection of permissive cells. Furthermore, endogenous seminal levels of SEM1(86-107) correlate with donor-dependent variations in viral enhancement activity, and antibodies generated against SEM1(86-107) recognize endogenous amyloids in human semen. The amyloidogenic potential of SEM1(86-107) and its virus-enhancing properties are conserved among great apes, suggesting an evolutionarily conserved function. These studies identify SEM1(86-107) to be a key, HIV-enhancing amyloid species in human semen and underscore the dynamic nature of semen's HIV-enhancing activity. Importance: Semen, the most common vehicle for HIV transmission, enhances HIV infection in vitro, but how long it retains this activity has not been investigated. Semen naturally undergoes physiological changes over time, whereby it converts from a gel-like consistency to a more liquid form. This process, termed liquefaction, is characterized at the molecular level by site-specific and progressive cleavage of SEMs, the major components of the coagulum, by seminal proteases. We demonstrate that the HIV-enhancing activity of semen gradually decreases over the course of extended liquefaction and identify a naturally occurring semenogelin-derived fragment, SEM1(86-107), whose levels correlate with virus-enhancing activity over the course of liquefaction. SEM1(86-107) amyloids are naturally present in semen, and synthetic SEM1(86-107) fibrils bind virions and are sufficient to enhance HIV infection. Therefore, by characterizing dynamic changes in the HIV-enhancing activity of semen during extended liquefaction, we identified SEM1(86-107) to be a key virus-enhancing component of human semen.
    No preview · Article · Apr 2014 · Journal of Virology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The self-assembly of Abeta peptides into a range of conformationally heterogeneous amyloid states represents a fundamental event in Alzheimer's disease. Within these structures oligomeric intermediates are considered to be particularly pathogenic. To test this hypothesis we have used a conformational targeting approach where particular conformational states, such as oligomers or fibrils, are recognized in vivo by state-specific antibody fragments. We show that oligomer targeting with the KW1 antibody fragment, but not fibril targeting with the B10 antibody fragment, affects toxicity in Abeta-expressing Drosophila melanogaster. The effect of KW1 is observed to occur selectively with flies expressing Abeta(1-40) and not with those expressing Abeta(1-42) or the arctic variant of Abeta(1-42) This finding is consistent with the binding preference of KW1 for Abeta(1-40) oligomers that has been established in vitro. Strikingly, and in contrast to the previously demonstrated in vitro ability of this antibody fragment to block oligomeric toxicity in long-term potentiation measurements, KW1 promotes toxicity in the flies rather than preventing it. This result shows the crucial importance of the environment in determining the influence of antibody binding on the nature and consequences of the protein misfolding and aggregation. While our data support to the pathological relevance of oligomers, they highlight the issues to be addressed when developing inhibitory strategies that aim to neutralize these states by means of antagonistic binding agents.
    Full-text · Article · Apr 2014
  • Tobias Aumüller · Marcus Fändrich
    [Show abstract] [Hide abstract]
    ABSTRACT: Amyloid fibrils are formed from polypeptide chains assembled into an organized fibrillar structure. Now, it has been shown that such fibrillar structures can also bind metal ions and catalyse chemical reactions.
    No preview · Article · Mar 2014 · Nature Chemistry
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Naturally occurring fragments of the abundant semen proteins prostatic acid phosphatase (PAP) and semenogelins form amyloid fibrils in vitro. These fibrils boost HIV infection and may play a key role in the spread of the AIDS pandemic. However, the presence of amyloid fibrils in semen remained to be demonstrated. Here, we use state of the art confocal and electron microscopy techniques for direct imaging of amyloid fibrils in human ejaculates. We detect amyloid aggregates in all semen samples and find that they partially consist of PAP fragments, interact with HIV particles and increase viral infectivity. Our results establish semen as a body fluid that naturally contains amyloid fibrils that are exploited by HIV to promote its sexual transmission.
    Full-text · Article · Feb 2014 · Nature Communications
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease is characterized by the deposition of amyloid-β peptide in the brain. N-terminal truncation resulting in the formation of AβN3pE and phosphorylation at serine 8 have been reported to modify aggregation properties of amyloid-β. Biochemically, soluble, dispersible, membrane-associated, and insoluble, plaque-associated amyloid-β aggregates have been distinguished. Soluble and dispersible amyloid-β aggregates are both in mixture with the extracellular or intracellular fluid but dispersible aggregates can be cleared from proteins in solution by ultracentrifugation. To clarify the role of phosphorylated amyloid-β and AβN3pE in soluble, dispersible, membrane-associated, and plaque-associated amyloid-β aggregates in the pathogenesis of Alzheimer's disease we studied brains from 21 cases with symptomatic Alzheimer's disease, 33 pathologically preclinical Alzheimer's disease cases, and 20 control cases. Western blot analysis showed that soluble, dispersible, membrane-associated and plaque-associated amyloid-β aggregates in the earliest preclinical stage of Alzheimer's disease did not exhibit detectable amounts of AβN3pE and phosphorylated amyloid-β. This stage was referred to as biochemical stage 1 of amyloid-β aggregation and accumulation. In biochemical amyloid-β stage 2, AβN3pE was additionally found whereas phosphorylated amyloid-β was restricted to biochemical amyloid-β stage 3, the last stage of amyloid-β aggregation. Phosphorylated amyloid-β was seen in the dispersible, membrane-associated, and plaque-associated fraction. All cases with symptomatic Alzheimer's disease in our sample fulfilled biochemical amyloid-β stage 3 criteria, i.e. detection of phosphorylated amyloid-β. Most, but not all, cases with pathologically preclinical Alzheimer's disease had biochemical amyloid-β stages 1 or 2. Immunohistochemistry confirmed the hierarchical occurrence of amyloid-β, AβN3pE, and phosphorylated amyloid-β in amyloid plaques. Phosphorylated amyloid-β containing plaques were, thereby, seen in all symptomatic cases with Alzheimer's disease but only in a few non-demented control subjects. The biochemical amyloid-β stages correlated with the expansion of amyloid-β plaque deposition and with that of neurofibrillary tangle pathology. Taken together, we demonstrate that AβN3pE and phosphorylated amyloid-β are not only detectable in plaques, but also in soluble and dispersible amyloid-β aggregates outside of plaques. They occur in a hierarchical sequence that allows the distinction of three stages. In light of our findings, it is tempting to speculate that this hierarchical, biochemical sequence of amyloid-β aggregation and accumulation is related to disease progression and may be relevant for an increasing toxicity of amyloid-β aggregates.
    No preview · Article · Feb 2014 · Brain

  • No preview · Article · Feb 2014 · Neurology Psychiatry and Brain Research
  • Christian Haupt · Dietmar Rudolf Thal · Uwe Horn · Marcus Fändrich
    [Show abstract] [Hide abstract]
    ABSTRACT: Conformational diseases, such as Alzheimer’s or Parkinson’s, are characterized by the misfolding of endogenous polypeptide chains into abnormal amyloid fibril conformations. To better analyze this process and its biological consequences and to generate tools for targeted interference in vitro and in vivo, we have biotechnologically generated a set of antibody fragments that are able to discriminate by binding between different amyloid assembly states.
    No preview · Article · Feb 2014 · BioSpektrum
  • [Show abstract] [Hide abstract]
    ABSTRACT: This chapter contains sections titled: Detection of Fibrillar Polymorphism The Structural Definition of Fibril Polymorphism The Two Classes of Fibril Polymorphism How Does Fibrillar Polymorphism Arise? The Interconversion of Fibril Polymorphs The Biological Implications of Fibril Polymorphism Summary Acknowledgments References
    No preview · Chapter · Jan 2013

Publication Stats

4k Citations
505.84 Total Impact Points

Institutions

  • 2014-2015
    • Universität Ulm
      • Institute of Pathology
      Ulm, Baden-Württemberg, Germany
  • 2008-2012
    • Max-Planck-Forschungsstelle für Enzymologie der Proteinfaltung
      Halle-on-the-Saale, Saxony-Anhalt, Germany
    • Martin Luther University of Halle-Wittenberg
      • Institute of Biochemistry and Biotechnology
      Halle-on-the-Saale, Saxony-Anhalt, Germany
  • 2006-2010
    • Leibniz Institute for Age Research - Fritz Lipmann Institute
      Jena, Thuringia, Germany
  • 2004
    • Massachusetts Institute of Technology
      Cambridge, Massachusetts, United States
  • 2001
    • University of Oxford
      • Chemical Research Laboratory
      Oxford, ENG, United Kingdom